【摘要】：炭疽病是由炭疽桿菌引起的一種高傳染性和致死率的疾病。炭疽毒素抗體治療能有效降低炭疽病的發(fā)病率和死亡率,已成為炭疽病治療的重要療法之一。瑞西巴庫(kù)是第一個(gè)獲批的單克隆抗毒素抗體,對(duì)于疑似感染者,可同時(shí)注射瑞西巴庫(kù)和炭疽疫苗以加強(qiáng)免疫。對(duì)于吸入性炭疽病,可與其他相關(guān)抗生素一起用于治療炭疽病。瑞西巴庫(kù)通過(guò)阻止炭疽毒素保護(hù)性抗原元件與宿主中相應(yīng)受體結(jié)合的方式,防止毒素對(duì)宿主造成傷害。臨床試驗(yàn)表明該藥使用安全,動(dòng)物實(shí)驗(yàn)證實(shí)該藥在治療與預(yù)防吸入性炭疽方面頗為有效。本文對(duì)炭疽病的病理生理特征和瑞西巴庫(kù)的作用機(jī)制、療效以及注意事項(xiàng)作簡(jiǎn)要概述。
[Abstract]:Anthrax is a highly infectious and fatal disease caused by Bacillus anthracis. Anthrax toxin antibody therapy can effectively reduce the incidence and mortality of anthrax, and has become one of the important treatments for anthrax. Rexibacu is the first approved monoclonal anti-toxin antibody, and for suspected patients, both Rexibacu and anthrax vaccines can be injected to enhance immunization. For inhaled anthracnose, it can be used with other antibiotics to treat anthracnose. By preventing anthrax toxin protective antigen elements from binding to the corresponding receptors in the host, Rexibacu prevents the toxin from harming the host. Clinical trials showed that the drug was safe to use, and animal experiments showed that it was effective in the treatment and prevention of inhaled anthrax. The pathophysiological characteristics of anthracnose and the mechanism, curative effect and attention of Rexi Baku are briefly summarized in this paper.
【作者單位】： 軍事醫(yī)學(xué)科學(xué)院放射與輻射醫(yī)學(xué)研究所;
【基金】：國(guó)家“重大新藥創(chuàng)制”科技重大專項(xiàng)(2012ZX09301003-001-007);國(guó)家“重大新藥創(chuàng)制”科技重大專項(xiàng)(2015ZX09501007);國(guó)家“重大新藥創(chuàng)制”科技重大專項(xiàng)(2015ZX09501008) 上海市科技支撐項(xiàng)目(13431901000)
【分類號(hào)】：R517.2

【參考文獻(xiàn)】

相關(guān)期刊論文 前1條

1 李亮亮;郭強(qiáng);徐俊杰;;炭疽的特異性治療藥物的研究進(jìn)展[J];中國(guó)生物制品學(xué)雜志;2014年08期

【相似文獻(xiàn)】

相關(guān)重要報(bào)紙文章 前1條

1 甘孜州駐自貢衛(wèi)�！�9+3”管理組 供稿;殷殷關(guān)愛(ài)如潮涌[N];甘孜日?qǐng)?bào)(漢文);2009年

，

本文編號(hào)：2275739